For those seeking to turn back the hands of time with a more youthful look, a new anti-wrinkle product claims to last twice as long as Botox.
Botox competitor, Daxxify, gains FDA approval as anti-wrinkle drug
Nashville-based Revance Therapeutics announced Thursday that the U.S. Food and Drug Administration approved its new treatment, Daxxify, noting that the effects can last about six months, or longer ...
Kate Middleton & Meghan Markle Reportedly Swear By This Product Instead of Botox — & It’s On Rare Sale for 30% Off
Botox can be a lot of money, and the results can always vary. You hear products that people call their go-to instead of botox, but hesitation is always around the corner. But this product is sworn by ...
FDA approves Botox competitor Daxxify to treat wrinkles
People wanting to keep wrinkles at bay will soon have a new option now that the U.S. Food and Drug Administration has approved the first competitor for Botox in decades.
A Longer-Acting Botox Competitor is Coming
A new, longer-acting competitor to Botox Cosmetic received its first FDA approval. Revance Therapeutics finally overcame manufacturing d ...
FDA OKs anti-wrinkle drug, a longer-lasting Botox competitor
The Food and Drug Administration (FDA) on Thursday approved the anti-wrinkle injection Daxxify, setting up competition for Botox, which has dominated the market for two decades. Manufacturer Revance ...
FDA Approves Botox Competitor That Lasts Longer
People wanting to keep wrinkles at bay will soon have a new option now that the U.S. Food and Drug Administration has approved the first competitor for Botox in decades. Daxxify, made by Revance ...
Botox rival can be ‘more broadly used’ in therapeutics: Revance CEO
Revance CEO Mark Foley joins Yahoo Finance Live to discuss the therapeutic company's anti-wrinkle Daxxify treatment, its multi-use purposes, and its competition with traditional Botox injections.
Revance Shares Jump 18% After FDA Approves Botox Rival Daxxify
The FDA approved Daxxify for temporary improvement of moderate to severe frown lines, Revance said in a Thursday morning statement. Shares of Revance climbed gradually Thursday afternoon, trading at ...